Clinical Trial Update: Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial update reports safety data for tofacitinib, an oral JAK inhibitor, in patients with Sjogren's syndrome, with results posted on 2025-1…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjogren Syndrome

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) | Conditions: Sjogren's Syndrome | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-18